SUNNYVALE, Calif., Dec. 6, 2018 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the new release of
its Accuray Precision® Treatment Planning System (TPS)
with the CyberKnife® VOLO™ Optimizer will enable
CyberKnife System customers to significantly improve operational
efficiency by reducing both the time to create high quality
treatment plans and the time it takes to deliver patient
treatments. The next-generation TPS with the optimizer will
facilitate the development of clinically optimal treatment plans up
to 90 percent faster than before and the delivery of the treatment
up to an estimated 50 percent faster than before, affording
clinicians more time to expand patient access to the highly precise
stereotactic body radiation therapy (SBRT) and stereotactic
radiosurgery (SRS) treatments the CyberKnife System delivers.
"Our hospital was one of the first in the U.S. to provide
treatment with the CyberKnife M6™ and InCise™ Multileaf Collimator
and we are continuing our legacy of innovation, focused on
positively transforming the care we deliver, with the upgrade to
the Accuray Precision TPS and CyberKnife VOLO Optimizer," said
Sujatha Pai, Chief Physicist, Penn
Medicine Lancaster General Health. "One of our goals in moving from
the MultiPlan® TPS to the Accuray Precision TPS and new
optimizer was to increase the speed with which we can create and
optimize treatment plans, and our experience to date is clearly
demonstrating we are achieving this goal. For example, our
physicists, Allison Lindsey and Dr.
Hong Xiang, say that with Precision
they were able to create an optimal prostate plan in just 45
minutes that would have taken 5-6 hours prior to the upgrade. In
general, we're finding it is easier to determine the best treatment
approach for each patient and it takes us less time to do so,
allowing us to provide SBRT and SRS treatments to more patients in
need."
The CyberKnife VOLO Optimizer builds on industry-established
treatment planning methods with new tools intended to assist in
delivering an exceptional clinical experience. Validated with input
from clinical users affiliated with regional and academic centers,
the goal of the optimizer is to 1) make planning faster, thus
increasing planning throughput and allowing better plans through
exploration of trade-offs and 2) improve the treatment delivery
throughput. With the CyberKnife VOLO Optimizer, clinicians are
expected to realize a substantial reduction in optimization time,
enabling them to create plans for multiple cases in the same day,
and helping to ensure the optimal treatment plan is created for
cancer and neurology cases spanning different diagnoses and tumor
sizes.
An internal Accuray evaluation comparing the Accuray Precision
TPS with CyberKnife VOLO Optimizer solution, to other TPS, either
for CyberKnife or other radiation therapy systems, has identified
important improvements including:
- Up to 50 percent reduction in SRS/SBRT treatment times, which
includes 'beam on' and imaging of the treatment target every 30
seconds or more, so clinicians can treat more patients each
day
- Up to 90 percent reduction in the time spent creating the
treatment plan, allowing clinicians to generate and evaluate more
plans each day, making it easier to identify the particular plan
that is right for each patient
"The new Accuray Precision TPS with CyberKnife VOLO Optimizer
represents a major step forward in the evolution of the CyberKnife
System in treatment speed, efficiency and ease of use. Clinicians
now have an option for delivering the same highly precise
radiosurgery treatments they have come to expect with the system
more quickly and for a wider range of patient cases," said Lionel
Hadjadjeba, M.D., Senior Vice President and Chief Customer
Experience Officer at Accuray. "We're thrilled with the results of
our internal evaluation, which has shown noteworthy reductions in
both treatment planning and delivery times compared to other TPS
for the CyberKnife® platform and treatment planning
software for other delivery systems. We believe the introduction of
the CyberKnife® VOLO™ Optimizer has the potential to
significantly change the way the platform is used in clinical
practice."
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, expected
improvements in treatment planning, optimization time, treatment
time, and treatment delivery throughput, changes in the way the
CyberKnife platform is used in clinical practice, and Accuray's
leadership position in radiation oncology innovation and
technologies. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties materialize,
or if any of the company's assumptions prove incorrect, actual
results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the company's
ability to achieve widespread market acceptance of its products,
including new product offerings; the company's ability to develop
new products or enhance existing products to meet customers' needs;
the company's limited long-term clinical data supporting the safety
and efficacy of its products for certain users and such other risks
identified under the heading "Risk Factors" in the company's
quarterly report on Form 10-Q, filed with the Securities and
Exchange Commission (the "SEC") on November
6, 2018 and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6662
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-cyberknife-system-treatment-delivery-times-up-to-50-percent-faster-with-software-upgrade-300760940.html
SOURCE Accuray Incorporated